Contents & References of Investigating the toxicity effects of single-walled carbon nanotubes on breast cancer cells in vitro
List:
Abstract. 1
Introduction. 2
Chapter One: Generalities
1-1- Breast cancer. 4
1-2- Epidemiology. 5
1-3- Etiology factors. 5
1-3-1- overweight. 6
1-3-2- Lack of physical activity. 7
1-3-3-alcohol. 7
1-3-4- diet. 8
1-3-5- Cigarettes 9
1-3-6- steroid hormones and their receptors. 9
1-3-6-1- steroid hormones. 9
1-3-6-2- receptors of steroid hormones. 10
1-3-6-3- History of pregnancy and breastfeeding. 11
1-3-6-4- estrogen. 12
1-3-6-5- hormone replacement therapy. 12
1-3-7- Using oral contraceptives. 13
1-3-8- Working at night and environmental factors. 14
1-3-9- age. 14
1-3-10- Gender. 15
1-3-11- History of being sexually active. 15
1-3-12- Family history. 16
1-3-13- Personal history. 16
1-3-14- breast cell changes, wound and breast injury. 17
1-3-15- consumption of diethyl acetylbestrol. 17
1-3-16- History of benign breast disease. 17
1-3-17- High-risk genes 18
1-3-18- High-risk syndromes 19
1-3-19- The role of HER2/neu antigen. 20
1-3-20- density of mammography. 20
1-4- Hypotheses of the formation and origin of tumors 20
1-5- Breast cancer heterogeneity. 21
1-6- types of breast cancer. 22
1-6-1-luminal breast cancer A and B. 22
1-6-2- HER2+ breast cancer: 22
1-6-3- pseudo-basal. 22
1-7- Staging of cancer. 22
1-7-1- zero stage 23
1-7-2- first stage. 23
1-7-3- The second stage. 23
1-7-4- The third stage. 24
1-7-5- the fourth step. 24
1-8- Nano in cancer treatment and prevention. 24
1-9- Carbon nanotubes. 26
1-9-1- Properties of carbon nanotubes. 26
1-9-2-Use as a drug carrier. 28
1-9-3- dispersing the carbon nanotube in the solvent. 28
1-9-4- carbon nanotube functionalization. 29
1-9-4-1- Kovalan method. 29
1-9-4-2- non-covalent method. 30
1-9-4-3-Pegylation to improve properties in biological applications. 31
Chapter Two: A Review of Past Texts
2-1- Administration, absorption and transfer of CNT. 33
2-2- intravenous administration. 34
2-3- Application of single-wall nanocarbon tube and biological safety. 35
2-3-1- Biosafety of single-walled nanotube as drug carrier. 36
2-4- Application in targeted treatment. 37
2-5- Application in gene delivery. 38
2-6- Application in targeted drug delivery systems for cancer treatment. 38
Chapter three: Materials and methods
3-1- Materials and methods 42
3-1-1- Materials 42
3-1-2- Properties of carbon nanoparticles. 43
3-2- Methods 45
3-2-1- Cell culture and treatment. 45
3-2-1-1- Cell lines used 45
General characteristics of the cell. 46
Name of the cell line. 46
3-2-1-2- Defreeze frozen cells. 47
3-2-1-3- Freezing cells 47
3-2-1-4- Required solutions and buffers 48
3-2-1-4-1- Salt phosphate buffer (PBS) 48
3-2-1-4-2- Complete culture medium. 48
3-2-1-5-Testing cells 49
3-2-1-5-1- Counting cells 49
3-2-1-5-3-Checking the viability of cells using the MTT method. 50
3-2-1-5-4- Determination of IC-50. 51
3-2-1-5-5- measuring the release of lactate dehydrogenase enzyme into the culture medium. 52
3-2-1-5-6- Staining with 33258 Hoechst 52
Chapter Four: Results
4-1- Toxicity induced by single-walled nanotube with cyclic functional group on HUV-EC-C, MCF-7 and PC12 cells 54
4-2- Investigating the effect of single-walled nanotube with functional group Cyclic on the fate of MCF-7 cells by MTT assay 55 4-3- Investigating the effect of single-walled nanotube with cyclic functional group on the fate of MCF-7 cells by LDH assay 59 4-4- Investigating the effect of single-walled nanotube with cyclic functional group on the fate of HUVEC cells by MTT assay 62 4-5- Investigating the effect of single-walled nanotube with functional group Cyclic on the fate of HUVEC cells by LDH assay 65 4-6- Investigating the effect of single-walled nanotubes with cyclic functional group on PC12 cells by MTT assay. 69
4-6- Review. 69
4-6- Investigating the effect of single-walled nanotubes with a cyclic functional group on PC12 cells by measuring LDH. 71
4-7- Toxicity induced by carboxylated single-walled nanotubes on HUV-EC-C, MCF-7 and PC12 cells. 75
4-8- Investigating the effect of carboxylated single-walled nanotubes on the fate of MCF-7 cells by MTT assay. 76
4-9- Investigating the effect of carboxylated single-walled nanotubes on the fate of MCF-7 cells by measuring LDH. 77
4-100- Investigating the effect of carboxylated single-walled nanotubes on the fate of HUVEC cells by MTT assay. 78
4-11- Investigating the effect of carboxylated single-walled nanotubes on the fate of HUVEC cells by measuring LDH. 79
4-12- Investigating the effect of carboxylated single-walled nanotubes on the fate of PC12 cells by MTT assay. 80
4-13- Investigating the effect of carboxylated single-walled nanotubes on the fate of PC12 cells by LDH assay. 81
4-14- induction of apoptotic death. 82
Chapter Five: Discussion and Suggestions
5-1-Discussion. 85
5-2-Proposition 94
Resources. 95
English summary. 102
Appendixes. 103
Source:
1. Abdellatif, KH., Abdelall, E., Abdelgawad, M., Ahmed, M., Bakr, R., 2014, Synthesis and anticancer activity of some new pyrazolo[3,4-d]pyrimidin-4-one derivatives, Molecules, Vol. 19, P.3297-3309.
2. . Aguas, F., Martins, A., Gomes, T., De Sousa, M., Silva, D., 2006, Portuguese enopause Society and Portuguese Gynecology Society, 2005, Prophylaxis approach to a symptomatic post-menopausal women breast cancer, Maturitas, Vol. 52, p. S23-31.
3. Aiello, EJ., Buist, DS., White, E., Porter, PL., 2005, Association between
mammographic breast density and breast cancer tumor characteristics, Cancer
Epidemiol Biomarkers Prev,Vol. 14, p. 662-668.
4. Ali S, Coombes RC, 2002, Endocrine-responsive breast cancer and strategies
for combating resistance, Nat Rev Cancer, Vol. 2, p.101-112.
5. Antoniou, A., Pharoah, PD., Narod, S., 2003, Average risks of breast and ovarian cancer
associated with BRCA1 or BRCA2 mutations detected in case series unselected for family
history: a combined analysis of 22 studies, Am J Hum Genet, Vol.72, P.1117-30.
6.Borresen-Dale, AL., 2003, TP53 and breast cancer, Hum Mutat, Vol.21, P.292-300
7. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies, 2004, Am J Hum Genet, Vol.74, P.1175-82.
8. Cheng, J., [etal]., 2008, Reversible accumulation of PEGylated single-walled carbon nanotubes in the mammalian nucleus, ACS Nano, Vol. 2, P.2085-2094.
9. Cole, MP., Jones, CT., Todd, ID., 1971, A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474, Br J Cancer, Vol. 25, p. 270-275.
10. Dumitrescu RG., Cotarla I., 2005, Understanding breast cancer risk where do
we stand in 2005? , J Cell Mol Med, Vol 9, P. 208-221.
11. Easton, DF.,[ et al]., 2007, Genome-wide association study identifies novel breast cancer susceptibility loci, Nature, Vol.447, P.1087-93.
12. Foldvari, M., Bagonluri, M., 2008, Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties, Nanomedicine, Vol.3, P.173-182. 13. Foldvari, M., Bagonluri, M., 2008, Carbon nanotubes as functional excipients for
nanomedicines: II. Drug delivery and biocompatibility issues, Nanomedicine, Vol. 3, P.183-200.
14. Georgakilas, V., Tzitzios, V., Gournis, D., Petridis, D., 2005, Attachment of magnetic nanoparticles on carbon nanotubes and their soluble derivatives, Chem Mater, Vol. 17, P.1613-1617.
15. Ghorab, M., Ragab, F., Alqasoumi, S., Alafeefy, A., Aboulmagd, S.